SLC19A3

Across TCGA pan-cancer cohorts, SLC19A3 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SLC19A3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SLC19A3 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC19A3 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

LUAD, LUSC, and KICH are the cancer types where SLC19A3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC19A3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−2.996	<.001	9	view →
LUSC	Female	II,III,IV	−3.434	<.001	8	view →
KICH	Male	II,III,IV	−1.750	<.001	8	view →
LIHC	Male	II,III,IV	−1.185	<.001	8	view →
COAD	All	IV	−1.027	.005	7	view →
BRCA	All	III,IV	−3.900	<.001	6	view →
HNSC	All	All	−0.435	.006	6	view →
STAD	Female	All	+1.622	.013	4	view →
CHOL	All	All	−1.113	.011	4	view →
KIRP	All	All	−0.702	.010	4	view →
BLCA	Male	All	−0.601	.010	4	view →
KIRC	Male	All	−0.573	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SLC19A3–LUAD

Open the LUAD breakdown →